PKO Investment Management Joint-Stock’s Moderna MRNA Stock Holding History

PKO Investment Management Joint-Stock’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,000	Closed	-$166K	–	207
2025 Q2	$166K	Hold	6,000	–	–	0.02%	173
2025 Q1	$170K	Hold	6,000	–	–	0.02%	173
2024 Q4	$249K	Hold	6,000	–	–	0.03%	153
2024 Q3	$401K	Buy	6,000 +4,300	+253%	+$395K	0.05%	144
2024 Q2	$202K	Sell	1,700 -1,800	-51%	-$228K	0.02%	162
2024 Q1	$375K	Sell	3,500 -23,500	-87%	-$2.37M	0.04%	148
2023 Q4	$2.69M	Sell	27,000 -14,000	-34%	-$1.18M	0.34%	53
2023 Q3	$4.23M	Sell	41,000 -2,305	-5%	-$257K	0.57%	29
2023 Q2	$5.26M	Buy	43,305 +35,605	+462%	+$4.75M	0.64%	27
2023 Q1	$1.18M	Buy	7,700 +6,200	+413%	+$1.02M	0.16%	102
2022 Q4	$269K	Sell	1,500 -1,500	-50%	-$245K	0.04%	129
2022 Q3	$355K	Sell	3,000 -171	-5%	-$25.9K	0.06%	122
2022 Q2	$453K	Hold	3,171	–	–	0.07%	112
2022 Q1	$546K	Hold	3,171	–	–	0.07%	105
2021 Q4	$805K	Buy	+3,171	New	+$927K	0.09%	99

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PKO Investment Management Joint-Stock's MRNA Position: Q3 2025 in Review

PKO Investment Management Joint-Stock sold out of Moderna (MRNA) in Q3 2025, closing a stake of 6,000 shares — an estimated $166K sold.

PKO Investment Management Joint-Stock first reported a position in MRNA in Q4 2021 and held it in 15 quarters. The position peaked at $5.26M in Q2 2023. 644 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

PKO Investment Management Joint-Stock reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
PKO Investment Management Joint-Stock sold 6,000 Moderna shares in Q3 2025, an estimated $166K.
PKO Investment Management Joint-Stock first reported a position in Moderna in Q4 2021 and held it in 15 quarters.
PKO Investment Management Joint-Stock's Moderna position peaked at $5.26M in Q2 2023.
644 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on PKO Investment Management Joint-Stock's 13F filing for Q3 2025, filed 27 Oct 2025.